FDA Participation At 3rd Developing CAPAs In The GCP Environment Conference, 24-25 January 2013, Arlington, VAMain Category: Conferences
Article Date: 15 Jan 2013 - 7:00 PST
FDA Participation At 3rd Developing CAPAs In The GCP Environment Conference, 24-25 January 2013, Arlington, VA
|Patient / Public:|
Dr. Jean Mulinde, Acting Senior Advisor, Division of Good Clinical Practice Compliance, Office of Scientific Investigations at CDER, FDA, has confirmed to present the following keynote address at the 3rd Developing CAPAs in the GCP Environment Conference on January 24-25, 2013 at the Westin in Arlington, VA.
KEYNOTE PRESENTATION: REGULATORY UPDATE
FDA's Expectations for Clinical CAPAs and Reponses to FDA Warnings
Jean Mulinde, MD, Acting Senior Advisor, Division of Good Clinical Practice Compliance, Office of Scientific Investigations, CDER, FDA
Overview of current inspections trends and follow-up
Commonly occurring deficiencies in CAPA
Essential event identification documentation at site and sponsor level
Preparing and providing acceptable responses to an FDA 483 or Warning Letter
Defining independent third party verification of a CAPA
Seats are limited and filling fast, so click here to reserve yours today. Use Priority Code C221PR
ADDITIONAL FEATURED SESSIONS:
CASE STUDY - CAPA SYSTEM IMPLEMENTATION IN A LARGE R&D ORGANIZATION
One Approach to Developing and Executing an Effective CAPA System to Support Clinical Quality
Pearl Boakye, Head, CAPA Management, BAYER
How and When to Assess Whether the Clinical CAPA was Effective to Determine Next Steps
Elizabeth Luczak, Vice President, Medical Regulatory Compliance, PFIZER, INC.
ROOT CAUSE ANALYSIS
Understanding the Purpose of a Root Cause Analysis and How to Effectively Conduct the Investigation
Venessa Galate, Associate Director, Therapeutic Area Clinical QA - Cardiovascular, JANSSEN PHARMACEUTICALS
ASSIGNING CRITICALITY & MITIGATING RISK
Establishing Criticality Levels Based on Risk to Effectively Prioritize the Clinical Root Cause Analysis and CAPA
Kevin Wilson, Root Cause Analysis and CAPA Consultant, ELI LILLY
DEFINING CLINICAL CAPA
Identifying and Recognizing the Many Different Definitions of Clinical CAPA and the Varying Criteria That are Used
Krista Kerr, Associate Director, Global Systems Quality Assurance, JANSSEN PHARMACEUTICALS
Plus interactive Panel Discussions where varying company types and sizes weigh in on the following topics:
- CONDUCTING AN EFFECTIVE RCA: Experts Share their Company's Processes, Best Practices and Lessons Learned when Conducting Root Cause Analyses
- IMPLEMENTING CAPA SYSTEMS: Varying Companies Share Challenges and Best Practices when Developing and Implementing a Clinical CAPA System
- ESCALATION AND CLOSE OUT: Comparing Varying Company's Criteria and Strategies for Assessing Clinical CAPA Effectiveness and Determining when to Escalate or Close Out
- CAPA DEFINITION AND INTERNAL RESPONSIBILITIES: How Different Companies Define Clinical CAPAs and the Responsibilities of Compliance and QA
HALF DAY INTERACTIVE WORKSHOPS:
Don't Miss our Pre-Conference Workshops. Choose your preferred topic from the following half-day workshops for intensive learning mixed with interactive activities.
WORKSHOP A -CAPA: THE FUNDAMENTALS
A Basic Overview of the Critical Elements of CAPA and the Processes at Each Stage
WORKSHOP B - CAPA IN GCP
Defining and Applying CAPA in the GCP Environment and Identifying Potential Challenges Unique to the Clinical Space
WHO SHOULD ATTEND:
C-Level, Vice President, Director, Manager and Team Leader level professionals form the following departments at Pharma/Biotech companies, Medical Device Companies, CROs and other Clinical Trial Service Providers:
Clinical Quality Assurance
Clinical Quality Control
The conference will also benefit:
Data Management and Computer Software Vendors
Westin Arlington Gateway
801 North Glebe Road
Arlington, VA 22203
Contact details for registration:
ExL Events, Inc.
555 8th Ave, Ste 310
New York, NY 10018
Visit our conferences section for the latest news on this subject.
ExL Pharma, a division of ExL Events, Inc., is the industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe, Latin America and various markets. Behind our diverse pharmaceutical event portfolio, ExL's experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality events designed to exceed the dynamic informational and networking needs of specific audiences and working groups.
23 May. 2013. <http://www.medicalnewstoday.com/releases/254958.php>
Please note: If no author information is provided, the source is cited instead.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.